Peptide Vaccine To Prevent Acquired Resistance In Patients With Advanced ALK+ NSCLC

This study is testing a peptide vaccine designed to prevent drug resistance in people with advanced non-small cell lung cancer (NSCLC) that has an ALK gene rearrangement. Patients are already on an ALK-targeting drug and are responding to it — the goal is to use the vaccine to prevent the cancer from becoming resistant. **You may be eligible if...** - You are 18 or older with confirmed Stage IV NSCLC with an ALK gene rearrangement - You are currently taking an ALK inhibitor (such as crizotinib, alectinib, brigatinib, or lorlatinib) and your cancer has been stable for at least 4 months - You do not have the specific ALK resistance mutations that the vaccine is targeting - Your overall health is good (ECOG 0-1) **You may NOT be eligible if...** - You have another active cancer requiring treatment in the past 3 years - You are on chronic oral steroids or other systemic immune-suppressing medications - You have symptomatic brain metastases or need increasing steroids for brain disease - You have active spinal cord compression Talk to your doctor to see if this trial is right for you.